reports
- Guy Sips
- Hilde Van Boxstael
- Livio Luyten
- Wim Hoste
- Wim Lewi
- Livio Luyten
Hal Trust Target hit again, upgrading to €168 on revised private valua...
HAL has hit our price target for the second time since our Buy rating in Apr'25, marking a +30% rally. Following the Sept'25 company note, we have revised our model to reflect: the improved sentiment in the offshore energy sector supporting a higher valuation for core holding Boskalis, and (ii) selective adjustments to peer multiples for other private assets. This drives our target NAV per share to €225 (from €218 in Sept'25). We maintain a relatively wide 25% target discount (down from 30% in...
- Hilde Van Boxstael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- Lynn Hautekeete
Nextensa Refinancing risks mitigated, cut to hold on SP performance
Nextensa announced the €35.95m disposal of its Gewerbepark Stadlau retail park in Vienna. Since the Bel Tower/Proximus announcement in early 2025, the company has accelerated its disposal program to address upcoming debt maturities (average term 2.6y) and ongoing capex commitments. Refinancing risks now appear largely mitigated. We expect FY25 results to come in ahead of our previous estimates, primarily driven by the strong share price performance of the nowdivested Retail Estates stake. On a r...
- Michiel Declercq
D'Ieteren PHE enters into exclusive negotiations for two acquisitions ...
PHE has entered into exclusive negotiations to acquire a 51% stake in two AD Parts distributors in Spain, Polaris and Regueira. Polaris and Regueira are major players in light vehicle spare parts distribution in Madrid, Galicia, Castile-La Mancha, Castile and León, Cantabria, and Asturias. The two entities generated € 340m in sales in 2025. This compares to PHE's current 12 month trailing revenue of € 2.84bn. Although no financials have been disclosed, the transaction will allow PHE to leverage ...
- Guy Sips
- Jacob Mekhael
- Jacob Mekhael
Onward Medical ARX-EX launch broadens, key ARC-IM data due 2H26 (model...
Onward enters 2026 with increased commercial momentum following FDA clearance for ARC-EX home use in SCI patients in November 2025, which expands access beyond clinics and is expected to accelerate adoption. Meanwhile, the company is advancing its implantable program, with ARC-IM interim data from the pivotal Empower BP trial in SCI patients with blood pressure instability expected in 2H26—an important catalyst that could accelerate development timelines. We roll over our model to 2026, adjustin...
- Guy Sips
Kinepolis Group One Battle After Another
Following weaker-than-expected December 2025 admissions in North America and Europe, we updated our Kinepolis visitor model to reflect a softer 4Q25 and FY25 than originally anticipated. In the US, December Box Office declined -2.3% y/y, resulting in a –6.9% quarter as an overcrowded release slate diluted demand across major titles. This drove FY25 admissions below expectations, despite a 1% y/y increase in Box Office revenue supported by premium pricing. We expect Canada to show the same patter...
- Jacob Mekhael
UCB Reiterates recently upgraded FY25 guidance
UCB highlighted its 2025 achievements, and reiterated its recently upgraded FY25 guidance (5 December 2025). This was the company's second guidance upgrade in 2025 and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS. This is further supported by Bimzelx reaching over 100K patients worldwide. Looking ahead, Bimzelx' expanded access in 2026 to include 36m additional covered li...
- Jacob Mekhael
Autolus Aucatzyl launch success, FY25 preliminary revenue in line with...
Yesterday before US market opens, Autolus announced preliminary unaudited 4Q25 and FY25 net product sales of Aucatzyl (obe-cel, CD19 CAR-T), and provided a business update. $ 75m in FY25 Aucatzyl sales is in line with CSS ($ 75.9m) and ahead of our estimate of $ 72.5m. We believe this figure makes Aucatzyl's first year on the market a success, and we view FY26 guidance of $ 120-135m as within reach. Pipeline wise, we look forward to initial data from the phase 1 trial of Aucatzyl in the difficul...
- Jacob Mekhael
argenx Vyvgart sBLA acceptance in seronegative gMG comes with priority...
argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 1...
- Mathijs Geerts Danau
Pharvaris Business update narrows topline prophylactic phase 3 data to...
Pharvaris provided a business update, which comes with narrowed guidance for the topline data from the phase 3 (CHAPTER-3) trial of deucrictibant in HAE prophylaxis, now expected in 3Q26 (previously 2H26). We're confident going into this readout, which we believe has a high probability of success based on the strong efficacy shown in phase 2. With the NDA filing in the on-demand setting on track for 1H26, and another phase 3 ongoing in AAE-C1INH, the product is set to address the broadest group ...
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Wim Hoste
- Wim Hoste
Ontex FIRST LOOK: Acceleration of CEO transition and launch of strateg...
Ontex decided to accelerate its earlier announced CEO transition plan with Mr Nielly, President of Ontex Europe, to become the new CEO immediately. Ontex announced the launch of a strategic review, which seems mainly directed to enhancing the company's performance at this stage. We still see larger strategic moves like a combination with a US-focused peer as an eventual end game for Ontex, given the limited structural growth of its industry and the limitations to operational improvements. Despit...
- Mathijs Geerts Danau
mdxhealth FIRST LOOK: FY25 highlights show revenue in line with guidan...
Mdxhealth provides insights into key FY25 parameters, with preliminary revenue landing at $ 109m (VA CSS: $ 108.5m) and YE cash at $ 29m (VA CSS: $ 34.5m). Revenue guidance for FY26 is set at a narrow yet ambitious range of $ 137-140m, implying a 26-28% y/y increase. Additionally, mdxhealth managed to amend the Exact Sciences payouts to be more back-end loaded bringing some ease to the cash position. We believe that mdxhealth is well-positioned for growth in 2026 now that the commercial engine i...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
argenx 2026 strategic priorities includes narrowed guidance for phase ...
argenx outlined its strategic priorities for 2026 and shared preliminary Vyvgart sales numbers coming in at $ 4.15b for FY25, more or less in line with CSS of $ 4.13b. Looking ahead, 2026 is set to be a catalyst rich year with 4 registrational readouts and we note that argenx provided more specific timeline guidance for each trial, while the earlier stage pipeline progresses with multiple new additions, and a biotech collaboration. We continue to see upside for the stock in 2026 and maintain our...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...
Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.
- Wim Hoste
Titan Titan America acquires Keystone Cement Company for c. $ 310m
Titan America announced an agreement to acquire Keystone for $310m, which will further expand its US operations and provides an attractive fit with the existing US footprint. The acquisition also fits well within TITAN's Forward 2029 Strategic plan which was presented in November 2025, and which targets to grow EBITDA by 62% to € 1bn by 2029 on a combination of organic growth initiatives and M&A in regions where the company has an established footprint and acquisitions offer sizeable synergies p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.